Beyond the Ward: Meet the Biotech Warriors Fighting DIPG

A cancer diagnosis is devastating, especially if it's a child and there is little that can be done in terms of treating it. Doctors will try to fight against the disease with every tool available at their disposal. But moving away from the hospital ward, there’s a different war happening. Bring in the biotech innovators who fight for these children when traditional medicine decides that there are no more options left for treatment. Their battle is against time, clinical bottlenecks and funding gaps.

For Sil Lutkewitte, CEO of Targepeutics, this mission deeply resonates with him. “We want these children to celebrate another birthday and then multiple birthdays,” Lutkewitte shares. “It’s personal for many reasons.”

Lutkewitte’s company, Targepeutics, mainly focuses on families with children who face Diffuse Intrinsic Pontine Glioma (DIPG), which is a rare and aggressive form of pediatric brain cancer. It presents deep within the brainstem where surgery is virtually impossible, leaving children and parents with barely any choices regarding treatment. Standard radiation therapy may be a temporary solution but its benefits are short-lived, leaving a median survival prognosis of just 9–12 months. As Lutkewitte notes, “Even a modest delay has real consequences.”

In comes GB13, an investigational therapy and Targepeutics’s potential answer to this pressing issue. GB13 is designed to selectively target cancer cells, weakening them beforehand to make subsequent radiation therapy far more effective. Its compelling science is important, but above all, the team wants to keep their focus on what the treatment could offer families: a genuine chance at survival.

So, what’s the problem? What Targepeutics faces now is known as the “Valley of Death”, the funding bottleneck where rare-disease treatments risk stalling before reaching clinical trials, highlighting the real tragedy in drug development. It is often these logistical hurdles that prevent treatments from reaching real patients. Targepeutics has already invested over $4 million to bring GB13 to the stage of human testing, but one last barrier remains: the $125,000 required for FDA-compliant cold storage and distribution to trial sites across the country.

“Raising the money we need is the sole-based limiter in our ability to get GB13 to the clinic for pediatric brain cancer,” Lutkewitte explains. “Targepeutics is not in this to become a big company making money; we’re in it to make an impact in the clinic.”

One company and one founder cannot carry the weight of this mission alone. As Lutkewitte emphasizes, “This won’t happen overnight. Many people will have to work together and sit around the same table.”

That need for collective action connects meaningfully to the core purpose of organizations like Music Beats Cancer. By connecting visionary innovators with a passionate community of supporters, initiatives such as Targepeutics’ campaign to raise the final $125,000 help bridge critical funding gaps so that life-saving science reaches the patients who need it most. It is more than just supporting a company and their work — it is about giving children with DIPG the chance to write their next chapter.

This article was written in collaboration with Music Beats Cancer, a non-profit organization focused on fundraising for cancer research.